Portland, United States
FloraWorks is a burgeoning player in the Biotechnology and Life Sciences sectors, strategically positioned at the forefront of cannabinoid innovation. Founded in 2019 and headquartered in the United States, the company is trailblazing with its science-backed approach to functional product development, famously captured in its slogan: "Science-backed cannabinoid innovation for brands | Minor Cannabinoid Supply | GMP & ISO Cert. | CBN, THCv, CBG, CBC, CBD".
Their rigorous research agenda has produced groundbreaking studies, including the industry's first peer-reviewed clinical trial validating CBN's efficacy for sleep. Offering GMP and ISO certified ingredients, FloraWorks is a trusted supplier for leading brands in customized, effect-based formulations. Their focus on minor cannabinoids like CBN, CBD, CBC, CBG, and THCv places them ahead of competitors in delivering targeted, consumer-backed solutions.
The company recently secured a $2.25M Series A investment on 01 June 2023, reinforcing investor confidence. Notably, this investment came from reputable sources, including The Arcview Group and Bonaventure Equity, underlining its growth potential. FloraWorks stands out not just as a supplier but as a scientific and strategic partner, committed to enhancing product performance, regulatory strategy, and client partnerships.
